GOSS Investors Have Opportunity to Join Gossamer Bio, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES–(BUSINESS WIRE)–$GOSS—The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims... Read more.
DNOW Investors Have Opportunity to Join DNOW Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES–(BUSINESS WIRE)–$DNOW—The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims... Read more.
Public Storage and Welltower Announce Strategic Data Science Partnership to Advance Application of AI in Real Estate Investing
FRISCO, Texas & TOLEDO, Ohio–(BUSINESS WIRE)–Public Storage (NYSE: PSA) and Welltower (NYSE: WELL) today announced a strategic data science partnership... Read more.
TVCMALL at MWC 2026: Leading Mobile Accessories Wholesale and Smarter Sourcing
BARCELONA, Spain–(BUSINESS WIRE)–As MWC Barcelona 2026 highlights the growing role of AI, connectivity, and smarter technology systems, the mobile accessories... Read more.
VZLA Investors Have Opportunity to Join Vizsla Silver Corp. Fraud Investigation with the Schall Law Firm
LOS ANGELES–(BUSINESS WIRE)–$VZLA—The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims... Read more.
SEVN Investors Have the Opportunity to Join Investigation of Seven Hills Realty Trust with the Schall Law Firm
LOS ANGELES–(BUSINESS WIRE)–$SEVN—The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims... Read more.
KORE Investors Have the Opportunity to Join Investigation of KORE Group Holdings, Inc. with the Schall Law Firm
LOS ANGELES–(BUSINESS WIRE)–$KORE—The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims... Read more.
AARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation With the Schall Law Firm
LOS ANGELES–(BUSINESS WIRE)–$AARD—The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims... Read more.
KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)
This is the first positive Phase 3 trial for WELIREG in earlier-stage disease, the first positive results for a HIF-2α inhibitor and immunotherapy combination and... Read more.
WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
This is the first positive Phase 3 trial of a HIF-2 alpha inhibitor in combination with a multi-targeted tyrosine kinase inhibitor, the first for patients with RCC... Read more.